Learn more about the LUMINOS-102 study design in advanced melanoma
See preclinical data and ongoing melanoma trial featured at ASCO 2021
Review phase 1 results presented at SITC and published in the JITC
Visit the LUMINOS-102 study protocol page on clinicaltrials.gov
Learn more about the LUMINOS-102 study design in advanced melanoma
See preclinical data and ongoing melanoma trial featured at ASCO 2021
Review phase 1 results presented at SITC and published in the JITC
Visit the LUMINOS-102 study protocol page on clinicaltrials.gov
Actively recruiting phase 2 trial of PVSRIPO for advanced, PD-1–refractory melanoma
PVSRIPO +/- anti–PD-1 therapy in advanced melanoma following PD-1/L1 failure
The LUMINOS-102 trial is designed to build on the results of the phase 1 trial of PVSRIPO, in which clinical responses were observed in injected and noninjected tumors in patients with unresectable, treatment-refractory melanoma.
See an overview of LUMINOS-102
Featured presentation at ASCO 2021: review data from a mouse model of advanced melanoma
Lauren Neighbours, PhD, RAC, from Istari Oncology reviews key findings from a preclinical study of murine PVSRIPO in a mouse model of advanced melanoma and what the findings mean for the ongoing LUMINOS-102 phase 2 clinical study of PVSRIPO with and without anti–PD-1 therapy in unresectable advanced melanoma.
Featured presentation at ASCO 2021: review data from a mouse model of advanced melanoma
Lauren Neighbours, PhD, RAC, from Istari Oncology reviews key findings from a preclinical study of murine PVSRIPO in a mouse model of advanced melanoma and what the findings mean for the ongoing LUMINOS-102 phase 2 clinical study of PVSRIPO with and without anti–PD-1 therapy in unresectable advanced melanoma.
Review the phase 1 results
Download the poster and peer-reviewed publication in the Journal for ImmunoTherapy of Cancer with the results of the phase 1 PVSRIPO trial in unresectable, treatment-refractory melanoma.
Review the phase 1 results
Download the poster and peer-reviewed publication in the Journal for ImmunoTherapy of Cancer with the results of the phase 1 PVSRIPO trial in unresectable, treatment-refractory melanoma.